These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38950910)

  • 21. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
    Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ
    Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular pathogenesis of metabolic dysfunction-associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis.
    Saito T; Tsuchishima M; Tsutsumi M; George J
    J Cell Mol Med; 2024 Jun; 28(12):e18491. PubMed ID: 38894579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and review.
    Leahy C; Osborne N; Shirota L; Rote P; Lee YK; Song BJ; Yin L; Zhang Y; Garcia V; Hardwick JP
    Biochem Pharmacol; 2024 Oct; 228():116241. PubMed ID: 38697309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Zazueta A; Valenzuela-Pérez L; Ortiz-López N; Pinto-León A; Torres V; Guiñez D; Aliaga N; Merino P; Sandoval A; Covarrubias N; Pérez de Arce E; Cattaneo M; Urzúa A; Roblero JP; Poniachik J; Gotteland M; Magne F; Beltrán CJ
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between Metabolic-Dysfunction-Associated Steatotic Liver Disease and Hepatic Cancer: Current Concepts and Future Challenges.
    Bader H; Yamin S; Alshahwan H; Farraj H; Maghnam J; Abu Omar Y
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892843
    [No Abstract]   [Full Text] [Related]  

  • 26. MASLD-Related HCC-Update on Pathogenesis and Current Treatment Options.
    Leyh C; Coombes JD; Schmidt HH; Canbay A; Manka PP; Best J
    J Pers Med; 2024 Mar; 14(4):. PubMed ID: 38672997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RASSF4 Attenuates Metabolic Dysfunction-Associated Steatotic Liver Disease Progression via Hippo Signaling and Suppresses Hepatocarcinogenesis.
    Xu C; Fang T; Qu J; Miao Y; Tian L; Zhang M; Zhuang H; Sun B; Chen L
    Cell Mol Gastroenterol Hepatol; 2024; 18(2):101348. PubMed ID: 38697356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight.
    Li A; Wang R; Zhao Y; Zhao P; Yang J
    Metabolites; 2024 Jun; 14(6):. PubMed ID: 38921460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinoma.
    Syamprasad NP; Jain S; Rajdev B; Panda SR; Kumar GJ; Shaik KM; Shantanu PA; Challa VS; Jorvekar SB; Borkar RM; Vaidya JR; Tripathi DM; Naidu VGM
    JHEP Rep; 2024 Feb; 6(2):100974. PubMed ID: 38283757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation.
    Min BH; Devi S; Kwon GH; Gupta H; Jeong JJ; Sharma SP; Won SM; Oh KK; Yoon SJ; Park HJ; Eom JA; Jeong MK; Hyun JY; Stalin N; Park TS; Choi J; Lee DY; Han SH; Kim DJ; Suk KT
    Gut Microbes; 2024; 16(1):2307568. PubMed ID: 38299316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions.
    Ma Y; Wang J; Xiao W; Fan X
    Front Med (Lausanne); 2024; 11():1410668. PubMed ID: 38895182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural history of metabolic dysfunction-associated steatotic liver disease.
    Lekakis V; Papatheodoridis GV
    Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Popov J; Despot T; Avelar Rodriguez D; Khan I; Mech E; Khan M; Bojadzija M; Pai N
    Nutrients; 2024 May; 16(11):. PubMed ID: 38892602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis.'.
    Li C; Wang T; Song J
    Curr Probl Cardiol; 2024 Jul; 49(7):102626. PubMed ID: 38718937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic signatures of metabolic dysfunction-associated steatotic liver disease in severely obese patients.
    Babu AF; Palomurto S; Kärjä V; Käkelä P; Lehtonen M; Hanhineva K; Pihlajamäki J; Männistö V
    Dig Liver Dis; 2024 Jun; ():. PubMed ID: 38825414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression.
    Piras IS; DiStefano JK
    Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38565287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct Gut Microbial Signature and Host Genetic Variants in Association with Liver Fibrosis Severity in Patients with MASLD.
    Satthawiwat N; Jinato T; Sutheeworapong S; Tanpowpong N; Chuaypen N; Tangkijvanich P
    Nutrients; 2024 Jun; 16(12):. PubMed ID: 38931155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the Adipose Tissue-Liver-Gut Microbiota Crosstalk to Cure MASLD.
    Gabbia D; De Martin S
    Biology (Basel); 2023 Nov; 12(12):. PubMed ID: 38132297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.